Lotiglipron

Description: Lotiglipron (PF-07081532) is an orally active, potent GLP-1R agonist that reduces blood glucose and body weight, potentially aiding in the study of type 2 diabetes mellitus (T2DM) and obesity. Target: Glucagon Receptor. Smiles: C[C@]1(OC2=C(C=CC=C2O1)C3CCN(CC=4N(C[C@@H]5CCO5)C=6C(N4)=CC=C(C(O)=O)C6)CC3)C7=CC=C(Cl)C=N7. References: Nauck MA,et al. Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists. Lancet. 2023 Aug 5,402(10400):429-431.